

Drug Utilization Review Board
(DUR Board)
Meeting – April 9, 2008 @ 6:00 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. March 12, 2008 DUR Minutes – Vote
 - B. March 13, 2008 DUR Recommendations Memorandum

Items to be presented by Dr. Gorman, Dr. McNeill, Chairman:

- 4. Update on DUR/MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for December 2007
 - B. Medication Therapy Management Services July 2007 – December 2007
 - C. Medication Coverage Activity Audit for March 2008
 - D. Help Desk Activity Audit for March 2008

Items to be presented by Dr. Browning, Dr. McNeill, Chairman:

- 5. Vote to Prior Authorize Tekturna HCT[®] – See Appendix C.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Gorman, Dr. McNeill, Chairman:

- 6. Vote to Prior Authorize Narcotic Analgesics – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. Gorman, Dr. McNeill, Chairman

7. **60 Day Notice to Prior Authorize Osteoporosis Medications – See Appendix E.**
 - A. Utilization Review
 - B. COP Recommendations
 - C. Product Overview
 - D. Potential Savings

Items to be presented by Dr. Patel, Dr. Gorman, Dr. McNeill, Chairman

8. **60 Day Notice to Prior Authorize Topical Antibiotics – See Appendix F.**
 - A. Utilization Review
 - B. Product Overview
 - C. COP Recommendations
 - D. Potential Savings

Items to be presented by Dr. Patel, Dr. Gorman, Dr. McNeill, Chairman

9. **30 Day Notice to Prior Authorize Allegra[®] ODT and Syrup and Update PBPA Category– See Appendix G.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

10. **30 Day Notice to Prior Authorize Pristiq[™] and Update PBPA Category – See Appendix H.**
 - A. Utilization Review
 - B. COP Recommendations
 - C. Potential Savings

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

11. **FDA and DEA Updates – See Appendix I.**

12. **Future Business**
 - A. Oral Antifungals
 - B. Methylphenidate Follow-Up
 - C. Asthma Utilization Review
 - D. Hemophilia Review
 - E. New Product Reviews

13. **Adjournment**